February 20, 2018 / 12:56 PM / 8 months ago

BRIEF-Esperion Reports Qtrly Loss Per Share $1.44

Feb 20 (Reuters) - Esperion Therapeutics Inc:

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

* ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION

* ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE ABOUT $130 TO $140 MILLION AT DEC 31, 2018

* ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $1.44 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below